Post

FDA clears Krystal Biotech’s IND for Type 1 AATD treatment KB408

The US Food and Drug Administration has approved Krystal Biotech’s Investigational New Drug (IND) for a Phase I clinical trial …

Jazz Pharma’s Enrylaze wins European approval for AML and LBL

The European Commission (EC) has approved Enrylaze (recombinant Erwinia asparaginase or crisantaspase) as an add-on therapy with chemotherapy for treating …

Over half of world’s population not covered by essential healthcare services

The World Health Organization (WHO) and the World Bank have published the 2023 Universal Health Coverage (UHC) Global Monitoring Report, …

Alvotech’s AVT05 in phase III rheumatoid arthritis study, as the sole candidate

The patent for Janssen’s second-generation, tumour necrosis factor-alpha (TNF)-a inhibitor Simponi (golimumab), is scheduled to expire in 2024 and in …

JURA Bio and Syena partner to develop TCR-based therapies

JURA Bio has entered a research collaboration with Replay cell therapy product company Syena for the development of T cell …